Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Multiple Cancer Types

This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
Colon, Rectal
II
Ciombor, Kristen
NCT03043313
VICCGI2035

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: